Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,514.37 65.12 0.40%
S&P 500 1,879.55 7.66 0.41%
NASDAQ 4,161.46 39.91 0.97%
Ticker Volume Price Price Delta
STOXX 50 3,189.63 -10.06 -0.31%
FTSE 100 6,675.69 -6.07 -0.09%
DAX 9,581.19 -18.90 -0.20%
Ticker Volume Price Price Delta
NIKKEI 14,546.27 157.50 1.09%
TOPIX 1,173.81 11.31 0.97%
HANG SENG 22,509.64 -221.04 -0.97%

Anacor Pharmaceuticals to Present at Deutsche Bank’s 38th Annual Healthcare Conference



  Anacor Pharmaceuticals to Present at Deutsche Bank’s 38th Annual Healthcare
  Conference

Deutsche Bank dbAccess Healthcare Conference 2013

Business Wire

PALO ALTO, Calif. -- May 23, 2013

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry, the
company’s Chief Executive Officer, will provide a company overview at Deutsche
Bank’s 38^th Annual Healthcare Conference on Thursday, May 30, 2013 at 2:10
p.m. ET in Boston, Massachusetts.

The event will be webcast live and may be accessed under “Events and
Presentations” on the Investors page of Anacor’s website at www.anacor.com. A
replay will also be available for three months following the presentation.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered eight compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — tavaborole, a topical antifungal for the treatment of
onychomycosis, and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other wholly-owned clinical product
candidates — AN2718 and AN2898, which are backup compounds to tavaborole and
AN2728, respectively, and AN3365 (formerly known as GSK2251052, or GSK ‘052),
an antibiotic for the treatment of infections caused by Gram-negative
bacteria, which previously was licensed to GlaxoSmithKline LLC, or GSK. GSK
has returned all rights to the compound to us and we are considering our
options for further development, if any, of this compound. We have discovered
three other compounds that we have out-licensed for further development — two
compounds for the treatment of animal health indications that are licensed to
Eli Lilly and Company and AN5568, also referred to as SCYX-7158, for human
African trypanosomiasis (HAT, or sleeping sickness), which is licensed to
Drugs for Neglected Diseases initiative, or DNDi. We also have a pipeline of
other internally discovered topical and systemic boron-based compounds in
development. For more information, visit http://www.anacor.com.

Contact:

Anacor Pharmaceuticals
DeDe Sheel, 650-543-7575
Director, Investor Relations and Corporate Communications
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement